Boston Scientific Honored as One of China's 'Top 10 Medical Humanities Enterprises' for Advancing Healthcare Innovation with Compassion

Beijing, March 18, 2022 /PRNewswire/ -- Today, the 7th Medical Scholars Annual Conference and the 2nd Physician Career Development Forum, hosted by The Physician Newspaper, officially opened in Beijing. The "High-Quality Development of Hospitals" session was held on the same day.·At the "Humanities Construction Forum," Boston Scientific was awarded the "Top Ten Medical Humanities Enterprises" to recognize and encourage its outstanding performance and contributions in leveraging its technological and resource advantages to promote high-quality development in China's medical industry, empower excellent medical professionals, benefit a wide range of patients, and continuously convey the spirit of medical humanities.

In response, Ms. Zhang Jun, President of Boston Scientific Greater China, stated that caring for life has always been the main theme of medical development, and "innovating for life" is the driving force behind Boston Scientific's relentless pursuit of breakthroughs. "This year marks the 25th anniversary of Boston Scientific’s presence in China, and the honor of being named one of the 'Top Ten Medically Humanitarian Enterprises' holds profound significance for us. It not only affirms our journey in China, where we have stood alongside medical professionals to benefit patients, but also strengthens our belief that we will play a significant role in supporting the future path of building 'Healthy China.' Moving forward, Boston Scientific will continue to ensure more people benefit from medical technology innovations through ongoing advancements and boundless care."

Accelerate Medical Technology Innovation and Introduction, Making Cutting-Edge Healthcare More Accessible

As a global leading medical technology company in the field of minimally invasive intervention, Boston Scientific Corporation always takes it as its mission to address unmet medical needs, committing to exploring technological innovation and local cooperation, continuously introducing international innovative achievements, and constantly reducing the "time difference" for Chinese patients and doctors to access cutting-edge global medical resources.

The latest generation of left atrial appendage closure device WATCHMAN FLX approved in China this year^TM[1], is the best testament to Boston Scientific's continuous innovation. As an innovative "tool" to help patients with atrial fibrillation prevent strokes, WATCHMAN^®It has won the Galien Award, known as the "Nobel Prize of the pharmaceutical industry." Since its first application in humans in 2002, it has accumulated 20 years of clinical experience. The latest generation product, WATCHMAN FLX, not only retains the revolutionary innovations of WATCHMAN but also further enhances surgical safety and effectiveness. According to the FLX real-world study results released at the CRT conference in the United States this February, clinical data analysis of over 16,000 patients with non-valvular atrial fibrillation confirmed a 97.6% implantation success rate for WATCHMAN FLX. The incidence of ischemic stroke within 45 days post-operation was only 0.28%, and the rate of serious adverse events within 7 days post-operation or before discharge (whichever occurred later) was just 0.37%.^[2]。

At the same time, in response to the high-incidence disease areas among Chinese patients, Boston Scientific is actively exploring accelerated pathways for the introduction of innovative products in collaboration with local partners. In Boao, Hainan, Boston Scientific is proactively engaging in "pilot programs" and real-world data research, speeding up the introduction of several innovative medical products, including the world's first thermal vapor therapy device for the treatment of benign prostatic hyperplasia.Rezūm^[3]Successfully obtained through real-world researchBatch, this technologyWith its advantages of short operation time, quick recovery, and high safety, the procedure can not only reduce the disease burden for a large number of middle-aged and elderly patients with benign prostatic hyperplasia in China, but also fully improve the utilization rate of grassroots medical resources, achieve the下沉of medical services, and bring good news to more patients in China.

Extensively Support the Growth of Local Medical Practitioners, Making Quality Medical Resources More Accessible

Beyond technological innovation, Boston Scientific deeply understands that the high-quality development of the medical industry relies on the cultivation of future-oriented medical talent. Adhering to the concept of "walking hand-in-hand with healthcare professionals," Boston Scientific leverages its global resources to continuously conduct professional education and extensive academic collaboration in China. The aim is to help medical workers master cutting-edge innovative technologies, grow together with local doctors through win-win cooperation, and contribute to the high-quality improvement of China's overall medical service standards.

Since 2013, Boston Scientific has established Innovation Training Institutes and Innovation Centers in Shanghai, Beijing, and Chengdu. It has also developed a multi-faceted training platform and system that integrates offline simulation training, online systematic courses, and 5G live training broadcasts, extensively cultivating outstanding clinical medical professionals. By launching the industry's first mobile education and training bus, Boston Scientific has further brought advanced medical technologies to extensive grassroots areas in China, truly achieving broad coverage and deep empowerment, and bridging the "last mile" for grassroots doctors to pursue advanced studies.

Technology has power, and medicine has warmth. Guided by the philosophy of innovating for life and standing shoulder to shoulder with medical professionals, Boston Scientific will continue to benefit the health of Chinese people in the next 25 years and work hand in hand with China's healthcare industry to draw the grand blueprint of "Healthy China."

^[1]China Medical Device Registration No. 20223030126

^[2] https://news.bostonscientific.com/2022-02-28-Late-Breaking-Study-Results-Reinforce-Positive-Real-World-Outcomes-with-the-WATCHMAN-FLX-TM-LAAC-Device

^[3]Registration No. 20223010122, Registration No. 20223010123

About Boston Scientific

Boston Scientific Corporation is committed to innovation for life. We are dedicated to innovative medical solutions that improve the lives of patients worldwide. For more than four decades, Boston Scientific has consistently led the development of the global medical technology industry by providing a wide range of high-performance medical solutions that meet the urgent needs of patients, while reducing healthcare costs. For more detailed information, please visit the company's website:www.bostonscientific.cn

About Boston Scientific Greater China

Boston Scientific established its China headquarters in Shanghai in 1997 and currently has branch offices in Beijing, Shanghai, Guangzhou, Chengdu, Hong Kong, and Taiwan. The company's core businesses encompass cardiac intervention, structural heart disease, cardiac rhythm management and electrophysiology, endoscopic intervention, peripheral and tumor intervention, urology and pelvic floor health, respiratory products, and more. Upholding its tradition as an innovation leader, Boston Scientific is committed to becoming a respected medical technology company that meets the needs of doctors and patients, demonstrates innovative vitality, and delivers high-quality medical products and services for prevention, diagnosis, and treatment. For more detailed information, please visit the company’s website:www.bostonscientific.cn